Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITAGORE: Pip/Tazo or Temocillin vs Meropenem for ESBL Sepsis
NCT05565222Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of piperacillin + tazobactam and temocillin in sepsis and septic shock (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Mortality at 30 days. Started Mar 2023; status: recruiting.
02
Drugs
piperacillin + tazobactamtemocillin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT05565222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565222.